GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles (GALA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02262416|
Recruitment Status : Unknown
Verified October 2014 by Queensland Fertility Group.
Recruitment status was: Not yet recruiting
First Posted : October 13, 2014
Last Update Posted : October 13, 2014
In-Vitro Fertilisation (IVF) is the term commonly applied to a form of treatment for infertility that involves controlled ovarian hyperstimulation, egg maturation, egg collection, fertilisation, embryo culture and finally embryo transfer. The period after egg collection is called luteal phase. In Australia, vaginal progesterone is routinely used to support the lining of the uterus so that it is susceptible to implantation of the embryos.
More recently, there has been some suggestion that additional supplementation of luteal phase with GnRH agonist increases clinical pregnancy and live birth rate. These studies are however heterogeneous and results were inconsistent.
This study is a prospective randomised controlled trial of additional GnRH agonist in luteal phase of antagonist cycle. The primary hypothesis is that GnRH agonist increases the number of live birth . The secondary hypothesis is that this increases the clinical pregnancy rate, on-going pregnancy rate, without affecting the miscarriage rate, ovarian hyperstimulation rate and multiple pregnancy rate.
|Condition or disease||Intervention/treatment||Phase|
|Infertility||Drug: leuprolide||Phase 3|
In-vitro fertilization has been used since 1978 to treat women with infertility. It involves controlled ovarian stimulation, egg maturation, egg collection, fertilization and embryo culture and finally embryo culture. The luteal phase is the latter phase of the menstrual cycle which begins with the formation of the corpora lutea and ends in either pregnancy or luteolysis. The main hormone associated with this stage is progesterone, which is significantly higher during the luteal phase than other phases of the cycle. In the IVF setting, however, luteal phase deficiency is present and over the last 40 years various regimens have been used to support luteal phase of the cycle. Progesterone is currently widely used for this purpose and has shown to be effective in improving pregnancy and live birth rate (Van der Linden 2011).
There have been various other regimen used for luteal support in an attempt to further enhance luteal phase support such as oestrogen, HCG and GnRH agonist. The recent Cochrane study showed a significant benefit from addition of GnRH agonist to progesterone versus progesterone alone for the outcomes of live birth, clinical pregnancy and ongoing pregnancy. (Van Der Linden 2011) However, the conclusion derived from the metaanalysis were derived from limited number of studies that used various types additional luteal phase support, which also included a myriad of agonist and antagonist IVF cycles. Only ICSI cycles were included in the antagonist cycles.
A gonadotropin-releasing hormone (GnRH) agonist is a synthetic peptide that interacts with the GnRH hormone receptor to elicit its biologic response, the release of the pituitary hormones, FHS and LH. The exact mechanism of how GnRH could potentially increase pregnancy rate is unknown. Tesarik et al performed a randomised study in which addition of GnRH agonist increases implantation rate in donor recipient discounted the theory that GnRH acted on corpora lutea. It is suggested that GnRH acts directly on embryo to secrete BHCG hence enhances implantation. A prospective randomised study that was performed by Isik et al showed a promising result of use of GnRH agonist administration in the luteal phase of GnRH antagonist cycle (n=164). In this study, cases received 0.5mg leuprolide acetate in addition to 600mg micronised progesterone day 6 after ICSI compared to control group who received micronisd progesterone only. The study showed clinical pregnancy rate of 40% in cases vs 20% in control group. The increased number of multiple pregnancies in these studies could be partly explained by multiple embryos transferred. Answer is needed to determine if multiple pregnancy rate is higher if single embryo transfer is executed.
The studies performed by Tesarik et al and Isik et al showed promising increase in live birth rate and clinical pregnancy rates in antagonist cycles. Both studies were performed in clinical settings that were vastly different from Australia: multiple embryos were transferred, multiple luteal phase support were used in addition to progesterone and multiple pregnancy rates were high. Given the significant increase in pregnancy rate (>10%) were observed in these studies, if the increase is real, a RCT in Australia setting is needed prior to implementation of this intervention.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Prospective Randomised Controlled Trial of GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles|
|Study Start Date :||January 2015|
|Estimated Primary Completion Date :||January 2016|
|Estimated Study Completion Date :||January 2016|
Placebo Comparator: controls
Normal saline of equivalent volume
Active Comparator: case
0.5mg Leuprolide acetate injection
Other Name: lucrin
- live birth [ Time Frame: 1 year ]live birth
- on-going pregnancy [ Time Frame: 3 months ]+ve fetal heart rate at nuchal scan
- pregnancy [ Time Frame: 2 weeks ]positive serum pregnancy test
- Ovarian hyperstimulation syndrome [ Time Frame: 3 months ]hospitalisation due to the condition
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02262416
|Queensland Fertility Group|
|Brisbane, Queensland, Australia, 4000|